<clinical_study>
<study_id>
<org_name>
  Lilly
</org_name>
<org_full_name>
  Eli Lilly and Company
</org_full_name>
<org_study_id>
  4015
</org_study_id>
<secondary_id>
  B9E-MC-JHQS
</secondary_id>
<nct_id>
  NCT00191100
</nct_id>
</study_id>
<is_fda_regulated>
  Yes
</is_fda_regulated>
<is_section_801>
  Yes
</is_section_801>
<delayed_posting>
  No
</delayed_posting>
<brief_title>
<textblock>
  Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix
</textblock>
</brief_title>
<official_title>
<textblock>
  Phase 3 Randomized Comparison of Concurrent Gemcitabine, Cisplatin, and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Cancer of the Cervix Stages IIB to IVA
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  Eli Lilly and Company
</agency>
</lead_sponsor>
</study_sponsor>
<resp_party>
<name_title>
  Chief Medical Officer
</name_title>
<organization>
  Eli Lilly
</organization>
</resp_party>
<oversight_info>
<regulatory_authority>
  Mexico: National Institute of Public Health, Health Secretariat
</regulatory_authority>
</oversight_info>
<brief_summary>
<textblock>
  The purpose of this study is to compare the effectiveness of two methods of treating cancer of the cervix. Half the patients will receive gemcitabine plus cisplatin while undergoing radiation therapy, followed by adjuvant gemcitabine and cisplatin and the other half will receive cisplatin along with radiation therapy without adjuvant therapy.
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
</textblock>
</detailed_descr>
<status_block>
<status>
  Completed
</status>
<date>
  2008-10
</date>
</status_block>
<start_date>
<date>
  2002-05
</date>
</start_date>
<last_follow_up_date
 type="Actual"
>
<date>
  2008-04
</date>
</last_follow_up_date>
<primary_compl_date
 type="Actual"
>
<date>
  2008-04
</date>
</primary_compl_date>
<phase_block>
<phase>
  Phase 3
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Randomized
</design>
<design>
  Open Label
</design>
<design>
  Active Control
</design>
<design>
  Parallel Assignment
</design>
<design>
  Efficacy Study
</design>
<number_of_arms>
  2
</number_of_arms>
<primary_outcome>
<measure>
  Number of Participants With Progressive Disease or Death Due to Any Cause at 3 Years
</measure>
<time_frame>
  Tumor assessments at baseline, weekly during chemoradiation &amp; brachytherapy, on Day 1 of adjuvant Cycles 1&amp;2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively
</time_frame>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<secondary_outcome>
<measure>
  Number of Participants With Progressive Disease or Death Due to Disease Under Study at Various Time Points
</measure>
<time_frame>
  Tumor assessments at baseline, weekly during chemoradiation &amp; brachytherapy, on Day 1 of adjuvant Cycles 1&amp;2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Local Failure Rate
</measure>
<time_frame>
  Tumor assessments at baseline, weekly during chemoradiation &amp; brachytherapy, on Day 1 of adjuvant Cycles 1&amp;2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Tumor Response Rate
</measure>
<time_frame>
  Tumor assessments at baseline, weekly during chemoradiation &amp; brachytherapy, on Day 1 of adjuvant Cycles 1&amp;2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Number of Participants Who Died From Any Cause at Various Time Points
</measure>
<time_frame>
  baseline to date of death from any cause (includes 60 month follow-up period)
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Number of Participants With Progressive Disease or Death Due to Any Cause at Various Time Points
</measure>
<time_frame>
  Tumor assessments at baseline, weekly during chemoradiation &amp; brachytherapy, on Day 1 of adjuvant Cycles 1&amp;2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<enrollment
 type="Actual"
>
  515
</enrollment>
<condition>
  Cancer of Cervix
</condition>
<arm_group>
<arm_group_label>
  1
</arm_group_label>
<arm_type>
  Experimental
</arm_type>
<description>
<textblock>
  Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and
  Gemcitabine 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and
  Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
 
 
 
  Brachytherapy, 30-35 Gy over 1 week
 
  Two week rest period with no chemotherapy or radiation
 
  Cisplatin, 50 mg/m2, intravenous (IV), day 1 of 21 day cycle for two 21-day cycles and
  Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
  2
</arm_group_label>
<arm_type>
  Active Comparator
</arm_type>
<description>
<textblock>
  Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and
  Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
 
  Brachytherapy, 30-35 Gy over 1 week
</textblock>
</description>
</arm_group>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Gemcitabine
</primary_name>
<description>
<textblock>
</textblock>
</description>
<arm_group_label>
  1
</arm_group_label>
<other_name>
  LY188011
</other_name>
<other_name>
  Gemzar
</other_name>
</intervention>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Cisplatin
</primary_name>
<description>
<textblock>
</textblock>
</description>
<arm_group_label>
  1
</arm_group_label>
<arm_group_label>
  2
</arm_group_label>
</intervention>
<intervention>
<intervent_type>
  Radiation
</intervent_type>
<primary_name>
  Brachytherapy
</primary_name>
<description>
<textblock>
  Brachytherapy, 30-35 Gy over 1 week
</textblock>
</description>
<arm_group_label>
  1
</arm_group_label>
<arm_group_label>
  2
</arm_group_label>
</intervention>
<intervention>
<intervent_type>
  Radiation
</intervent_type>
<primary_name>
  Pelvic radiation
</primary_name>
<description>
<textblock>
  Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
</textblock>
</description>
<arm_group_label>
  1
</arm_group_label>
<arm_group_label>
  2
</arm_group_label>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria:
    - diagnosed with cancer of cervix
    - tumor that can be measured 
    - no previous treatment with chemotherapy or radiation for this cancer
    - Karnofsky Performance Status Score &gt;=70
    - able to give written consent
    - willing and able to participate in the study, both during the active treatment and the follow-up period.
 
  Exclusion Criteria:
    - impairment such as hearing loss from prior cisplatin therapy
    - damage to nerves such as being unable to distinguish hot and cold to touch
    - used other experimental medication in past 30 days
    - lab test results are not within the limits required for this study 
    - pregnancy or breast-feeding or possibility of becoming pregnant during this study and not using an approved method of birth control.
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<gender>
  Female
</gender>
<minimum_age>
  18 Years
</minimum_age>
<maximum_age>
  70 Years
</maximum_age>
</eligibility>
<investigator>
<role>
  Study Director
</role>
<name>
  Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
</name>
<affiliation>
<agency>
  Eli Lilly
</agency>
</affiliation>
</investigator>
<contact>
<name>
  There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
</name>
<phone>
  1-317-615-4559
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Buenos Aires
</city>
<state>
</state>
<zip>
</zip>
<country>
  Argentina
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Sarajevo
</city>
<state>
</state>
<zip>
</zip>
<country>
  Bosnia and Herzegovina
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Mumbai
</city>
<state>
</state>
<zip>
</zip>
<country>
  India
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Mexico City
</city>
<state>
</state>
<zip>
</zip>
<country>
  Mexico
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Karachi
</city>
<state>
</state>
<zip>
</zip>
<country>
  Pakistan
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Lima
</city>
<state>
</state>
<zip>
</zip>
<country>
  Peru
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Bangkok
</city>
<state>
</state>
<zip>
</zip>
<country>
  Thailand
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<see_also>
<annotation>
<textblock>
  Lilly Clinical Trial Registry
</textblock>
</annotation>
<url>
  http://www.lillytrials.com
</url>
</see_also>
<initial_release_date>
  2005-09-12
</initial_release_date>
<last_release_date>
  2009-03-30
</last_release_date>
<init_results_release_date>
  2009-03-30
</init_results_release_date>
<clinical_result>
<baseline>
<baselinemeasures>
<baselinemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<dispersionspread>
  9.5
</dispersionspread>
<parametervalue>
  46.1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<dispersionspread>
  9.8
</dispersionspread>
<parametervalue>
  45.8
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<dispersionspread>
  9.2
</dispersionspread>
<parametervalue>
  46.5
</parametervalue>
</reportedvalue>
</reportedvalues>
</measurecategory>
</measurecategories>
<parametertype>
  Mean
</parametertype>
<title>
  Age Continuous
</title>
<unitofmeasure>
  years
</unitofmeasure>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  515.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  259
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  256
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Female
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  0.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Male
</title>
</measurecategory>
</measurecategories>
<parametertype>
  Number
</parametertype>
<title>
  Gender, Male/Female
</title>
<unitofmeasure>
  participants
</unitofmeasure>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  56.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  27
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  29
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Pakistan
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  59.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  28
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  31
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Mexico
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  35.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  17
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  18
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Argentina
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  67.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  34
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  33
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Thailand
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  60.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  29
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  31
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Peru
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  116.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  60
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  56
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  India
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  61.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  33
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  28
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Bosnia and Herzegovina
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  61.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  31
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  30
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Panama
</title>
</measurecategory>
</measurecategories>
<parametertype>
  Number
</parametertype>
<title>
  Region of Enrollment
</title>
<unitofmeasure>
  participants
</unitofmeasure>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  233.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  114
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  119
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Moderately Differentiated
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  92.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  48
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  44
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Poorly Differentiated
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  138.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  69
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  69
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Unknown
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  2.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  2
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Undifferentiated
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  50.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  26
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  24
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Well Differentiated
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Number
</parametertype>
<title>
  Study Specific Characteristic
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<othertitle>
  Grade of Histological Diagnosis
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  1.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Unknown (Missing)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  1.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  70 - Unable to carry on normal activity
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  17.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  8
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  9
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  80 - Activity with effort; some signs of disease
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  292.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  147
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  145
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  90 - Normal activity; minor signs of disease
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  204.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  103
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  101
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  100 - Normal no complaints; no evidence of disease
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Classifies patients according to their functional impairment. Scores range from 0-100, the lower the score, the worse the survival for most serious illnesses.
</textblock>
</measuredescription>
<parametertype>
  Number
</parametertype>
<title>
  Study Specific Characteristic
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<othertitle>
  Karnofsky Performance Status Scale
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  32.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  17
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  15
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Adenocarcinoma of Cervix
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  397.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  198
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  199
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Adeno/Squamous Cell Carcinoma
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  1.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Other - Poorly Differentiated Carcinoma
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  85.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  43
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  42
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Other - Squamous
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Number
</parametertype>
<title>
  Study Specific Characteristic
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<othertitle>
  Pathological Diagnosis
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  172.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  87
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  85
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Western Asian
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  62.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  33
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  29
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Caucasian
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  67.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  34
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  33
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  East/Southeast Asian
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  214.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  105
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  109
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Hispanic
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Number
</parametertype>
<title>
  Study Specific Characteristic
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<othertitle>
  Race/Ethnicity
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  2.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage IIIA
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  188.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  94
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  94
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage IIIB
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  316.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  160
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  156
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage IIB
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  9.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  4
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  5
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage IVA
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Number
</parametertype>
<title>
  Study Specific Characteristic
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<othertitle>
  Stage of Disease
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<dispersionspread>
  6.6
</dispersionspread>
<parametervalue>
  154.9
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<dispersionspread>
  6.6
</dispersionspread>
<parametervalue>
  155.2
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<dispersionspread>
  6.7
</dispersionspread>
<parametervalue>
  154.6
</parametervalue>
</reportedvalue>
</reportedvalues>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<title>
  Study Specific Characteristic
</title>
<unitofmeasure>
  centimeters
</unitofmeasure>
<othertitle>
  Height
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<dispersionspread>
  12.2
</dispersionspread>
<parametervalue>
  61.8
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<dispersionspread>
  11.3
</dispersionspread>
<parametervalue>
  61.2
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<dispersionspread>
  13.0
</dispersionspread>
<parametervalue>
  62.4
</parametervalue>
</reportedvalue>
</reportedvalues>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<title>
  Study Specific Characteristic
</title>
<unitofmeasure>
  kilograms
</unitofmeasure>
<othertitle>
  Weight
</othertitle>
</baselinemeasure>
</baselinemeasures>
<baselinereportinggroups>
<baselinereportinggroup
 id="Baseline-BaselineRptGroup.1"
>
<description>
<textblock>
  Gemcitabine: 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
 
 
 
  Brachytherapy, 30-35 Gy over 1 week
 
  Two week rest period with no chemotherapy or radiation
 
  Cisplatin, 50 mg/m2, IV, day 1 of 21 day cycle for two 21-day cycles and
  Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles
</textblock>
</description>
<subjectsanalyzed>
  259
</subjectsanalyzed>
<title>
  Gemcitabine/Cisplatin/Radiation
</title>
</baselinereportinggroup>
<baselinereportinggroup
 id="Baseline-BaselineRptGroup.2"
>
<description>
<textblock>
  Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
 
  Brachytherapy, 30-35 Gy over 1 week
</textblock>
</description>
<subjectsanalyzed>
  256
</subjectsanalyzed>
<title>
  Cisplatin/Radiation
</title>
</baselinereportinggroup>
</baselinereportinggroups>
<totalbaselinereportinggroup
 id="Baseline-TotalBaselineRptGroup"
>
<subjectsanalyzed>
  515
</subjectsanalyzed>
<title>
  Total
</title>
</totalbaselinereportinggroup>
</baseline>
<certainagreement>
<otherdetails>
</otherdetails>
<pisponsoremployee>
  No
</pisponsoremployee>
<restrictiontype>
  GT60
</restrictiontype>
<restrictiveagreement>
  Yes
</restrictiveagreement>
</certainagreement>
<lastupdatetimestamp>
  2009-05-22T15:25:42-04:00
</lastupdatetimestamp>
<outcomemeasures>
<outcomemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  55
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  83
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  3 Years: Number of Patients with Event
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  149
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  141
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  3 Years: Number of Patients at Risk
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Original outcome was Progression-Free Survival (PFS) probability at 3 years. PFS=time from baseline to progressive disease (PD) or death from any cause. Probability is not an accepted &quot;Measure Type&quot;, so number of progression-free patients still at risk and cumulative number of patients that had an event (PD or death of any cause) are presented.
</textblock>
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  Tumor assessments at baseline, weekly during chemoradiation &amp; brachytherapy, on Day 1 of adjuvant Cycles 1&amp;2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively
</timeframe>
<title>
  Number of Participants With Progressive Disease or Death Due to Any Cause at 3 Years
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Primary
</measuretype>
<outcomemeasureanalyses>
<measureanalysis>
<outcomereportinggroups>
<outcomereportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</outcomereportinggroupid>
<outcomereportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.2
</outcomereportinggroupid>
</outcomereportinggroups>
<cilowerlimit>
  0.010
</cilowerlimit>
<cipctvalue>
  95
</cipctvalue>
<ciupperlimit>
  0.179
</ciupperlimit>
<dispersiontype>
</dispersiontype>
<dispersionvalue>
</dispersionvalue>
<estimatecomment>
<textblock>
  Difference in progression-free survival probability between Gem/Cis/Rad and Cis/Rad. The difference in PFS probability between the two treatment arms can also be presented as a percentage (ie, PFS at 3 years was 9.5% better in the Gem/Cis/Rad arm).
</textblock>
</estimatecomment>
<groupdescription>
</groupdescription>
<noninferioritytestcomment>
</noninferioritytestcomment>
<othermethodname>
  Z Statistic
</othermethodname>
<othertypename>
  PFS Probability Difference at 3 Years
</othertypename>
<parametertype>
  Other
</parametertype>
<parametervalue>
  0.095
</parametervalue>
<pvalue>
  0.029
</pvalue>
<pvaluecomment>
<textblock>
  The p-value is two-sided and was tested at the 0.05 significance level.
</textblock>
</pvaluecomment>
<statisticalmethod>
  Other
</statisticalmethod>
<statisticaltestcomment>
</statisticaltestcomment>
<testednoninferiority>
  No
</testednoninferiority>
</measureanalysis>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.1-OutcomeRptGroup.1"
>
<description>
<textblock>
  Gemcitabine: 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
 
 
 
  Brachytherapy, 30-35 Gy over 1 week
 
  Two week rest period with no chemotherapy or radiation
 
  Cisplatin, 50 mg/m2, IV, day 1 of 21 day cycle for two 21-day cycles and
  Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles
</textblock>
</description>
<subjectsanalyzed>
  259
</subjectsanalyzed>
<title>
  Gemcitabine/Cisplatin/Radiation
</title>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.1-OutcomeRptGroup.2"
>
<description>
<textblock>
  Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
 
  Brachytherapy, 30-35 Gy over 1 week
</textblock>
</description>
<subjectsanalyzed>
  256
</subjectsanalyzed>
<title>
  Cisplatin/Radiation
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Intention-to-treat population includes all randomized participants. Participants were analyzed according to treatment they were randomly assigned.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  5
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  8
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  3 Months: Number of Patients with Event
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  221
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  238
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  3 Months: Number of Patients at Risk
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  10
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  25
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  6 Months: Number of Patients with Event
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  204
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  218
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  6 Months: Number of Patients at Risk
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  21
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  44
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  12 Months: Number of Patients with Event
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  186
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  195
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  12 Months: Number of Patients at Risk
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  24
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  62
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  18 Months: Number of Patients with Event
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  176
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  170
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  18 Months: Number of Patients at Risk
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  31
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  69
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  24 Months: Number of Patients with Event
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  167
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  158
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  24 Months: Number of Patients at Risk
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  40
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  78
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  36 Months: Number of Patients with Event
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  149
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  141
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  36 Months: Number of Patients at Risk
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Original outcome was Time to Progressive Disease (TTPD), which is the time from baseline to event (progressive disease or death due to study disease). The median TTPD was not achieved and therefore the cumulative number of participants with event (and those still at risk) at various time points are presented.
</textblock>
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  Tumor assessments at baseline, weekly during chemoradiation &amp; brachytherapy, on Day 1 of adjuvant Cycles 1&amp;2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively
</timeframe>
<title>
  Number of Participants With Progressive Disease or Death Due to Disease Under Study at Various Time Points
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
<measureanalysis>
<outcomereportinggroups>
<outcomereportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</outcomereportinggroupid>
<outcomereportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.2
</outcomereportinggroupid>
</outcomereportinggroups>
<cilowerlimit>
</cilowerlimit>
<cipctvalue>
  95
</cipctvalue>
<ciupperlimit>
</ciupperlimit>
<dispersiontype>
</dispersiontype>
<dispersionvalue>
</dispersionvalue>
<estimatecomment>
</estimatecomment>
<groupdescription>
</groupdescription>
<noninferioritytestcomment>
</noninferioritytestcomment>
<othermethodname>
</othermethodname>
<othertypename>
</othertypename>
<parametertype>
</parametertype>
<parametervalue>
</parametervalue>
<pvalue>
  0.0008
</pvalue>
<pvaluecomment>
</pvaluecomment>
<statisticalmethod>
  Log Rank
</statisticalmethod>
<statisticaltestcomment>
</statisticaltestcomment>
<testednoninferiority>
  No
</testednoninferiority>
</measureanalysis>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.2-OutcomeRptGroup.1"
>
<description>
<textblock>
  Gemcitabine: 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
 
 
 
  Brachytherapy, 30-35 Gy over 1 week
 
  Two week rest period with no chemotherapy or radiation
 
  Cisplatin, 50 mg/m2, IV, day 1 of 21 day cycle for two 21-day cycles and
  Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles
</textblock>
</description>
<subjectsanalyzed>
  259
</subjectsanalyzed>
<title>
  Gemcitabine/Cisplatin/Radiation
</title>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.2-OutcomeRptGroup.2"
>
<description>
<textblock>
  Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
 
  Brachytherapy, 30-35 Gy over 1 week
</textblock>
</description>
<subjectsanalyzed>
  256
</subjectsanalyzed>
<title>
  Cisplatin/Radiation
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Intent-to-treat population includes all randomized patients. Patients were analyzed according to treatment they were randomly assigned.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  29
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  41
</parametervalue>
</reportedvalue>
</reportedvalues>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Local failure rate (LFR) was defined as the the proportion of per-protocol participants who had progressive disease (PD) in the cervix or pelvis. Since proportion is not an acceptable Measure Type, the number of (a) participants who progressed in the cervix or pelvis, and (b) the number of participants in each arm is presented. (LFR=a/b)
</textblock>
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  Tumor assessments at baseline, weekly during chemoradiation &amp; brachytherapy, on Day 1 of adjuvant Cycles 1&amp;2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively
</timeframe>
<title>
  Local Failure Rate
</title>
<unitofmeasure>
  Number patients with PD in cervix/pelvis
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
<measureanalysis>
<outcomereportinggroups>
<outcomereportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</outcomereportinggroupid>
<outcomereportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.2
</outcomereportinggroupid>
</outcomereportinggroups>
<cilowerlimit>
</cilowerlimit>
<cipctvalue>
  95
</cipctvalue>
<ciupperlimit>
</ciupperlimit>
<dispersiontype>
</dispersiontype>
<dispersionvalue>
</dispersionvalue>
<estimatecomment>
</estimatecomment>
<groupdescription>
</groupdescription>
<noninferioritytestcomment>
</noninferioritytestcomment>
<othermethodname>
</othermethodname>
<othertypename>
</othertypename>
<parametertype>
</parametertype>
<parametervalue>
</parametervalue>
<pvalue>
  0.123
</pvalue>
<pvaluecomment>
<textblock>
  The p-value is two-sided and was tested at the 0.05 significance level.
</textblock>
</pvaluecomment>
<statisticalmethod>
  Fisher Exact
</statisticalmethod>
<statisticaltestcomment>
</statisticaltestcomment>
<testednoninferiority>
  No
</testednoninferiority>
</measureanalysis>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.3-OutcomeRptGroup.1"
>
<description>
<textblock>
  Gemcitabine: 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
 
 
 
  Brachytherapy, 30-35 Gy over 1 week
 
  Two week rest period with no chemotherapy or radiation
 
  Cisplatin, 50 mg/m2, IV, day 1 of 21 day cycle for two 21-day cycles and
  Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles
</textblock>
</description>
<subjectsanalyzed>
  257
</subjectsanalyzed>
<title>
  Gemcitabine/Cisplatin/Radiation
</title>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.3-OutcomeRptGroup.2"
>
<description>
<textblock>
  Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
 
  Brachytherapy, 30-35 Gy over 1 week
</textblock>
</description>
<subjectsanalyzed>
  253
</subjectsanalyzed>
<title>
  Cisplatin/Radiation
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Per protocol population included all randomized patients with: Histological diagnosis of cancer of cervix; No previous chemotherapy or radiation therapy; Presence of bidimensionally measurable disease, at least 2 cm in diameter; Treatment with at least one dose of study chemotherapy. Patients were analyzed according to treatment actually received.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  223
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  217
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Complete Response
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  22
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  20
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Partial Response
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Tumor response rate (TRR) defined as proportion of qualified responder patients with confirmed complete or partial response. Since proportion is not an acceptable Measure Type, results are presented as number of (a) patients who achieved a complete or partial response, and (b) number of patients in qualified responders population per arm (TRR=a/b).
</textblock>
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  Tumor assessments at baseline, weekly during chemoradiation &amp; brachytherapy, on Day 1 of adjuvant Cycles 1&amp;2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively
</timeframe>
<title>
  Tumor Response Rate
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
<measureanalysis>
<outcomereportinggroups>
<outcomereportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.1
</outcomereportinggroupid>
<outcomereportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.2
</outcomereportinggroupid>
</outcomereportinggroups>
<cilowerlimit>
</cilowerlimit>
<cipctvalue>
  95
</cipctvalue>
<ciupperlimit>
</ciupperlimit>
<dispersiontype>
</dispersiontype>
<dispersionvalue>
</dispersionvalue>
<estimatecomment>
</estimatecomment>
<groupdescription>
</groupdescription>
<noninferioritytestcomment>
</noninferioritytestcomment>
<othermethodname>
</othermethodname>
<othertypename>
</othertypename>
<parametertype>
</parametertype>
<parametervalue>
</parametervalue>
<pvalue>
  0.250
</pvalue>
<pvaluecomment>
<textblock>
  The p-value is two-sided and was tested at the 0.05 significance level.
</textblock>
</pvaluecomment>
<statisticalmethod>
  Fisher Exact
</statisticalmethod>
<statisticaltestcomment>
</statisticaltestcomment>
<testednoninferiority>
  No
</testednoninferiority>
</measureanalysis>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.4-OutcomeRptGroup.1"
>
<description>
<textblock>
  Gemcitabine: 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
 
 
 
  Brachytherapy, 30-35 Gy over 1 week
 
  Two week rest period with no chemotherapy or radiation
 
  Cisplatin, 50 mg/m2, IV, day 1 of 21 day cycle for two 21-day cycles and
  Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles
</textblock>
</description>
<subjectsanalyzed>
  256
</subjectsanalyzed>
<title>
  Gemcitabine/Cisplatin/Radiation
</title>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.4-OutcomeRptGroup.2"
>
<description>
<textblock>
  Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
 
  Brachytherapy, 30-35 Gy over 1 week
</textblock>
</description>
<subjectsanalyzed>
  254
</subjectsanalyzed>
<title>
  Cisplatin/Radiation
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Qualified Responders population included all randomized patients with: Histological diagnosis of cancer of cervix; No previous chemotherapy or radiation therapy; Presence of bidimensionally measurable disease, at least 2 cm in diameter; Treatment with at least one dose of study chemotherapy. Patients were analyzed according to treatment assigned.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  3
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  3 Months: Number of Patients with Event
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  253
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  254
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  3 Months: Number of Patients at Risk
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  9
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  4
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  6 Months: Number of Patients with Event
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  241
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  248
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  6 Months: Number of Patients at Risk
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  22
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  25
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  12 Months: Number of Patients with Event
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  226
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  222
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  12 Months: Number of Patients at Risk
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  33
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  46
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  18 Months: Number of Patients with Event
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  207
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  195
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  18 Months: Number of Patients at Risk
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  39
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  58
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  24 Months: Number of Patients with Event
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  200
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  182
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  24 Months: Number of Patients at Risk
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  53
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  75
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  36 Months: Number of Patients with Event
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  175
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  158
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  36 Months: Number of Patients at Risk
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Original outcome was Overall Survival, which was defined as time from baseline to death from any cause.
</textblock>
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  baseline to date of death from any cause (includes 60 month follow-up period)
</timeframe>
<title>
  Number of Participants Who Died From Any Cause at Various Time Points
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
<measureanalysis>
<outcomereportinggroups>
<outcomereportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</outcomereportinggroupid>
<outcomereportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</outcomereportinggroupid>
</outcomereportinggroups>
<cilowerlimit>
</cilowerlimit>
<cipctvalue>
  95
</cipctvalue>
<ciupperlimit>
</ciupperlimit>
<dispersiontype>
</dispersiontype>
<dispersionvalue>
</dispersionvalue>
<estimatecomment>
</estimatecomment>
<groupdescription>
</groupdescription>
<noninferioritytestcomment>
</noninferioritytestcomment>
<othermethodname>
</othermethodname>
<othertypename>
</othertypename>
<parametertype>
</parametertype>
<parametervalue>
</parametervalue>
<pvalue>
  0.0224
</pvalue>
<pvaluecomment>
</pvaluecomment>
<statisticalmethod>
  Log Rank
</statisticalmethod>
<statisticaltestcomment>
</statisticaltestcomment>
<testednoninferiority>
  No
</testednoninferiority>
</measureanalysis>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.5-OutcomeRptGroup.1"
>
<description>
<textblock>
  Gemcitabine: 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
 
 
 
  Brachytherapy, 30-35 Gy over 1 week
 
  Two week rest period with no chemotherapy or radiation
 
  Cisplatin, 50 mg/m2, IV, day 1 of 21 day cycle for two 21-day cycles and
  Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles
</textblock>
</description>
<subjectsanalyzed>
  259
</subjectsanalyzed>
<title>
  Gemcitabine/Cisplatin/Radiation
</title>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.5-OutcomeRptGroup.2"
>
<description>
<textblock>
  Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
 
  Brachytherapy, 30-35 Gy over 1 week
</textblock>
</description>
<subjectsanalyzed>
  256
</subjectsanalyzed>
<title>
  Cisplatin/Radiation
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Intent-to-treat population includes all randomized patients. Patients were analyzed according to treatment they were randomly assigned.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  8
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  8
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  3 Months: Number of Patients with Event
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  221
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  238
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  3 Months: Number of Patients at Risk
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  14
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  25
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  6 Months: Number of Patients with Event
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  204
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  218
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  6 Months: Number of Patients at Risk
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  29
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  45
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  12 Months: Number of Patients with Event
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  186
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  195
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  12 Months: Number of Patients at Risk
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  34
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  63
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  18 Months: Number of Patients with Event
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  176
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  170
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  18 Months: Number of Patients at Risk
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  42
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  72
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  24 Months: Number of Patients with Event
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  167
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  158
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  24 Months: Number of Patients at Risk
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  55
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  83
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  36 Months: Number of Patients with Event
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  149
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  141
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  36 Months: Number of Patients at Risk
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Original outome was Progression-Free Survival, which was defined as time from baseline to progressive disease or death due to any cause.
</textblock>
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  Tumor assessments at baseline, weekly during chemoradiation &amp; brachytherapy, on Day 1 of adjuvant Cycles 1&amp;2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively
</timeframe>
<title>
  Number of Participants With Progressive Disease or Death Due to Any Cause at Various Time Points
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
<measureanalysis>
<outcomereportinggroups>
<outcomereportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</outcomereportinggroupid>
<outcomereportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.2
</outcomereportinggroupid>
</outcomereportinggroups>
<cilowerlimit>
</cilowerlimit>
<cipctvalue>
  95
</cipctvalue>
<ciupperlimit>
</ciupperlimit>
<dispersiontype>
</dispersiontype>
<dispersionvalue>
</dispersionvalue>
<estimatecomment>
</estimatecomment>
<groupdescription>
</groupdescription>
<noninferioritytestcomment>
</noninferioritytestcomment>
<othermethodname>
</othermethodname>
<othertypename>
</othertypename>
<parametertype>
</parametertype>
<parametervalue>
</parametervalue>
<pvalue>
  0.0227
</pvalue>
<pvaluecomment>
</pvaluecomment>
<statisticalmethod>
  Log Rank
</statisticalmethod>
<statisticaltestcomment>
</statisticaltestcomment>
<testednoninferiority>
  No
</testednoninferiority>
</measureanalysis>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.6-OutcomeRptGroup.1"
>
<description>
<textblock>
  Gemcitabine: 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
 
 
 
  Brachytherapy, 30-35 Gy over 1 week
 
  Two week rest period with no chemotherapy or radiation
 
  Cisplatin, 50 mg/m2, IV, day 1 of 21 day cycle for two 21-day cycles and
  Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles
</textblock>
</description>
<subjectsanalyzed>
  259
</subjectsanalyzed>
<title>
  Gemcitabine/Cisplatin/Radiation
</title>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.6-OutcomeRptGroup.2"
>
<description>
<textblock>
  Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
 
  Brachytherapy, 30-35 Gy over 1 week
</textblock>
</description>
<subjectsanalyzed>
  256
</subjectsanalyzed>
<title>
  Cisplatin/Radiation
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Intent-to-treat population includes all randomized patients. Patients were analyzed according to treatment they were randomly assigned.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
</outcomemeasure>
</outcomemeasures>
<participantflow>
<participantflowgroups>
<flowgroup
 id="ParticipantFlow-ParticipantFlowGroup.1"
>
<description>
<textblock>
  Gemcitabine: 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
 
 
 
  Brachytherapy, 30-35 Gy over 1 week
 
  Two week rest period with no chemotherapy or radiation
 
  Cisplatin, 50 mg/m2, IV, day 1 of 21 day cycle for two 21-day cycles and
  Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles
</textblock>
</description>
<title>
  Gemcitabine/Cisplatin/Radiation
</title>
</flowgroup>
<flowgroup
 id="ParticipantFlow-ParticipantFlowGroup.2"
>
<description>
<textblock>
  Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
  Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
 
  Brachytherapy, 30-35 Gy over 1 week
</textblock>
</description>
<title>
  Cisplatin/Radiation
</title>
</flowgroup>
</participantflowgroups>
<periods>
<period>
<completedmilestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  217
</subjectsachieve>
</milestoneachievement>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  244
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
</completedmilestone>
<dropwithdrawreasons>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  18
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
</otherreasonname>
<reasontype>
  Adverse Event
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  2
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  0
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
</otherreasonname>
<reasontype>
  Lost to Follow-up
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  0
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
  Patient Moved
</otherreasonname>
<reasontype>
  Other
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  9
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  3
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
</otherreasonname>
<reasontype>
  Withdrawal by Subject
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  2
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
  Protocol Entry Criteria Not Met
</otherreasonname>
<reasontype>
  Other
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  2
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
  Clinical Relapse
</otherreasonname>
<reasontype>
  Other
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  2
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
  Lack of Efficacy, Progressive Disease
</otherreasonname>
<reasontype>
  Other
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  0
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
  Lack of Efficacy, Stable Disease
</otherreasonname>
<reasontype>
  Other
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  3
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
</otherreasonname>
<reasontype>
  Physician Decision
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  2
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  0
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
  Death from Study Drug Toxicity
</otherreasonname>
<reasontype>
  Other
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
</otherreasonname>
<reasontype>
  Protocol Violation
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  0
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
  Death from Other Cause
</otherreasonname>
<reasontype>
  Other
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  0
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
  Reason Not Specified
</otherreasonname>
<reasontype>
  Other
</reasontype>
</dropwithdrawreason>
</dropwithdrawreasons>
<milestones>
</milestones>
<otherparticipantflowdetails>
<otherdetail>
<numbernotcompleted>
  42
</numbernotcompleted>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
</otherdetail>
<otherdetail>
<numbernotcompleted>
  12
</numbernotcompleted>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
</otherdetail>
</otherparticipantflowdetails>
<startedmilestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  259
</subjectsachieve>
</milestoneachievement>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  256
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
</startedmilestone>
<title>
  Overall Study
</title>
</period>
</periods>
</participantflow>
<pointofcontact>
<email>
</email>
<organizationname>
  Eli Lilly and Company
</organizationname>
<phoneextension>
</phoneextension>
<phonenumber>
  1-800-545-5979
</phonenumber>
<title>
  Chief Medical Officer
</title>
</pointofcontact>
<recordstatus>
PUBLISHED 
</recordstatus>
<reportedevents>
<frequencyreportingthreshold>
  5
</frequencyreportingthreshold>
<frequentadverseevents>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  233
</numevents>
<numsubjectsaffected>
  175
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  130
</numevents>
<numsubjectsaffected>
  115
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Anaemia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  271
</numevents>
<numsubjectsaffected>
  145
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  124
</numevents>
<numsubjectsaffected>
  114
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Leukopenia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  41
</numevents>
<numsubjectsaffected>
  31
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  32
</numevents>
<numsubjectsaffected>
  31
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Lymphopenia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  378
</numevents>
<numsubjectsaffected>
  193
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  78
</numevents>
<numsubjectsaffected>
  74
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Neutropenia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  79
</numevents>
<numsubjectsaffected>
  66
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  30
</numevents>
<numsubjectsaffected>
  30
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Thrombocytopenia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  115
</numevents>
<numsubjectsaffected>
  87
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  64
</numevents>
<numsubjectsaffected>
  57
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Abdominal pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  47
</numevents>
<numsubjectsaffected>
  44
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  36
</numevents>
<numsubjectsaffected>
  34
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Constipation
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  207
</numevents>
<numsubjectsaffected>
  159
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  151
</numevents>
<numsubjectsaffected>
  131
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Diarrhoea
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  19
</numevents>
<numsubjectsaffected>
  19
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  17
</numevents>
<numsubjectsaffected>
  14
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Dyspepsia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  280
</numevents>
<numsubjectsaffected>
  167
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  179
</numevents>
<numsubjectsaffected>
  155
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Nausea
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  22
</numevents>
<numsubjectsaffected>
  20
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  16
</numevents>
<numsubjectsaffected>
  16
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Proctalgia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  52
</numevents>
<numsubjectsaffected>
  47
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  25
</numevents>
<numsubjectsaffected>
  25
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Proctitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  248
</numevents>
<numsubjectsaffected>
  146
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  138
</numevents>
<numsubjectsaffected>
  121
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Vomiting
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  37
</numevents>
<numsubjectsaffected>
  28
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  9
</numevents>
<numsubjectsaffected>
  9
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Asthenia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  126
</numevents>
<numsubjectsaffected>
  80
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  67
</numevents>
<numsubjectsaffected>
  57
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Fatigue
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  38
</numevents>
<numsubjectsaffected>
  31
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  21
</numevents>
<numsubjectsaffected>
  21
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Pyrexia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  19
</numevents>
<numsubjectsaffected>
  17
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  10
</numevents>
<numsubjectsaffected>
  10
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Cystitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  33
</numevents>
<numsubjectsaffected>
  29
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  25
</numevents>
<numsubjectsaffected>
  22
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Vaginal infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  77
</numevents>
<numsubjectsaffected>
  72
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  67
</numevents>
<numsubjectsaffected>
  65
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Radiation skin injury
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  23
</numevents>
<numsubjectsaffected>
  19
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  8
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Alanine aminotransferase
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  26
</numevents>
<numsubjectsaffected>
  22
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  4
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Aspartate aminotransferase
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  81
</numevents>
<numsubjectsaffected>
  62
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  59
</numevents>
<numsubjectsaffected>
  51
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Creatinine renal clearance decreased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  61
</numevents>
<numsubjectsaffected>
  53
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  46
</numevents>
<numsubjectsaffected>
  44
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Anorexia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  34
</numevents>
<numsubjectsaffected>
  29
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  32
</numevents>
<numsubjectsaffected>
  30
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Back pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  18
</numevents>
<numsubjectsaffected>
  16
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  9
</numevents>
<numsubjectsaffected>
  8
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Myalgia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  47
</numevents>
<numsubjectsaffected>
  38
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  25
</numevents>
<numsubjectsaffected>
  23
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Headache
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  114
</numevents>
<numsubjectsaffected>
  95
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  85
</numevents>
<numsubjectsaffected>
  80
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Dysuria
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  17
</numevents>
<numsubjectsaffected>
  17
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  15
</numevents>
<numsubjectsaffected>
  14
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Pollakiuria
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  21
</numevents>
<numsubjectsaffected>
  20
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  17
</numevents>
<numsubjectsaffected>
  17
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Genital discharge
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  80
</numevents>
<numsubjectsaffected>
  71
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  68
</numevents>
<numsubjectsaffected>
  63
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Pelvic pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  84
</numevents>
<numsubjectsaffected>
  70
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  62
</numevents>
<numsubjectsaffected>
  62
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Vaginal discharge
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  157
</numevents>
<numsubjectsaffected>
  148
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  162
</numevents>
<numsubjectsaffected>
  157
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Vaginal haemorrhage
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  18
</numevents>
<numsubjectsaffected>
  18
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  16
</numevents>
<numsubjectsaffected>
  15
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Cough
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  16
</numevents>
<numsubjectsaffected>
  14
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  9
</numevents>
<numsubjectsaffected>
  9
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Pruritus
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  19
</numevents>
<numsubjectsaffected>
  19
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  21
</numevents>
<numsubjectsaffected>
  21
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Hypertension
</term>
</frequentevent>
</frequentadverseevents>
<interventiongroups>
<interventiongroup
 id="ReportedEvents-InterventionGroup.1"
>
<description>
<textblock>
  Gemcitabine: 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
                 Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
                 Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
 
 
 
                 Brachytherapy, 30-35 Gy over 1 week
 
                 Two week rest period with no chemotherapy or radiation
 
                 Cisplatin, 50 mg/m2, IV, day 1 of 21 day cycle for two 21-day cycles and
                 Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles
</textblock>
</description>
<numsubjectsfrequentevents>
  259
</numsubjectsfrequentevents>
<numsubjectsseriousevents>
  44
</numsubjectsseriousevents>
<title>
  Gemcitabine/Cisplatin/Radiation
</title>
</interventiongroup>
<interventiongroup
 id="ReportedEvents-InterventionGroup.2"
>
<description>
<textblock>
  Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks 
                 Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
 
                 Brachytherapy, 30-35 Gy over 1 week
</textblock>
</description>
<numsubjectsfrequentevents>
  251
</numsubjectsfrequentevents>
<numsubjectsseriousevents>
  17
</numsubjectsseriousevents>
<title>
  Cisplatin/Radiation
</title>
</interventiongroup>
</interventiongroups>
<seriousadverseevents>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  6
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Anaemia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  6
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Febrile neutropenia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  3
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Leukopenia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  2
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Neutropenia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Pancytopenia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  9
</numevents>
<numsubjectsaffected>
  9
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Thrombocytopenia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Cardio-respiratory arrest
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Ear and labyrinth disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Deafness neurosensory
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Eye disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Blindness
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  4
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Abdominal pain
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Constipation
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  17
</numevents>
<numsubjectsaffected>
  15
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  3
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Diarrhoea
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Haematemesis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Intestinal obstruction
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  3
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  3
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Nausea
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  4
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Proctitis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Tongue haemorrhage
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  6
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  4
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Vomiting
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Oedema
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  3
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  2
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Pyrexia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Diarrhoea infectious
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Infection
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Pneumonia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Sepsis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  3
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  3
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Urinary tract infection
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Radiation skin injury
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Blood bilirubin
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Blood creatinine
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  2
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Creatinine renal clearance decreased
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  2
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Dehydration
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Hyperglycaemia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  7
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Hypokalaemia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Hypomagnesaemia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  5
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Hyponatraemia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Fistula
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Neoplasms benign, malignant and unspecified (incl cysts and polyps)
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Tumour lysis syndrome
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Cerebral ischaemia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Depressed level of consciousness
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Leukoencephalopathy
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Dysuria
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Haematuria
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Renal failure
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Renal failure acute
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Urethral obstruction
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Pelvic pain
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Vaginal fistula
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  5
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  5
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Vaginal haemorrhage
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Pneumonia aspiration
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Leukocytoclastic vasculitis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  2
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Deep vein thrombosis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Hypertension
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  260
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  255
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MEDDRA 11.0
</sourcevocabulary>
<term>
  Hypotension
</term>
</seriousevent>
</seriousadverseevents>
</reportedevents>
</clinical_result>
</clinical_study>
